{
    "nct_id": "NCT05163028",
    "official_title": "A Phase 1, Open-Label, Dose Escalation of HBI-2376 in Patients With Advanced Malignant Solid Tumors Harboring KRAS or EGFR Mutations",
    "inclusion_criteria": "* Male or female at least 18 years of age at the time of signing the ICF prior to initiation of any study specific activities/procedures\n* Advanced malignant solid tumors with KRAS or EGFR mutations diagnosed by histology or cytology\n* Relapsed or refractory to, or intolerant of, or refuse approved or standard of care established therapy known to provide clinical benefit for disease\n* At least 1 measurable target lesion that meets the definition of RECIST v1.1\n* ECOG Performance Status of 0 or 1\n* Demonstrate adequate organ function\n* Must be able to swallow oral medications and must not have gastrointestinal abnormalities that significantly affect drug absorption\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of another concurrent malignancy within 3 years prior to study entry, unless the malignancy was treated with curative intent and the likelihood of relapse is <5% in 2 years Note: Subjects with a history of squamous or basal cell carcinoma of the skin or carcinoma in the situ of the cervix may be enrolled\n* Untreated or symptomatic central nervous system (CNS) metastases Note: Subjects with asymptomatic treated CNS metastases are eligible provided they have been clinically stable and not requiring steroids for at least 4 weeks\n* Clinically significant cardiovascular disease, including stroke or myocardial infarction within 6 months\n* Any unresolved Grade 2 or greater toxicity from previous anti-cancer therapy, except alopecia, within 4 weeks of first study treatment administration\n* Active autoimmune diseases or history of autoimmune diseases that may relapse\n* Pregnant or nursing\n* Prior treatment with any SHP2 inhibitors\n* Any condition that required systemic treatment with either corticosteroids (>10 mg daily of prednisone or equivalent) or other immunosuppressive medication â‰¤14 days before the first study treatment administration\n* Treatment with other investigational drugs/devices within 4 weeks prior to first study treatment administration",
    "miscellaneous_criteria": "Key"
}